Table 3.
Univariate analysis variables significant for local progression free survival in a cohort of 56 breast cancer patients with 94 brain metastases, treated by SRS.
| Estimated median LPFS (mts) | 95% CI |
p-value (log-rank) |
|||
|---|---|---|---|---|---|
| Lower bound | Upper bound | ||||
| Her 2 | Positive | 10.1 | 7.4 | 12.8 | < 0.0005 |
| Negative | 5.7 | 5.2 | 6.1 | ||
| ERHer2group | ER+Her2+ | 10.7 | 8.1 | 13.4 | 0.001 |
| ER−Her2+ | 9.528 | 7.7 | 11.3 | ||
| ER+Her2− | 5.1 | 4.7 | 5.4 | ||
| ER−Her2− | 5.7 | 5.4 | 6.0 | ||
| SRS dose prescribed | 12–16 Gy/1 fx | 7.1 | 3.8 | 10.4 | 0.006 |
| 18–20 Gy/1 fx | 8.6 | 7.6 | 9.6 | ||
| 21–24 Gy/1 fx | 9.4 | 4.5 | 14.3 | ||
| IMRS (24–30 Gy/3 fx) |
3.9 | 1.9 | 5.9 | ||
ER, estrogen receptor; fx, fraction; LPFS, local progression-free survival; mts, months.